Peter Vavassis

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 519 citations · Full text

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial

Timothy J. Whelan, Jim A. Julian, Tanya Berrang et al. · The Lancet · 2019 · 407 citations

Surgical Oncology, Breast Oncology, Radiation Therapy +11

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 280 citations · Full text

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial

Abdenour Nabid, Nathalie Carrier, Éric Vigneault et al. · European Journal of Cancer · 2020 · 54 citations

Urology, Radiation Therapy, Medicine +6

Hypofractionated Radiation Therapy for Breast Ductal Carcinoma In Situ

Lara Hathout, Tarek Hijal, Valérie Théberge et al. · International Journal of Radiation Oncology*Biology*Physics · 2013 · 43 citations

Radiation Medicine, Radiation Therapy, Medicine +3